The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation as convenient therapy to reduce glucose levels in blood preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments the invention provides orally administerable combination pharmaceutical formulations comprising at least one insulin sensitizer (e.g. a glitazone such as pioglitazone or rosi...

The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or...

The present invention relates to the field of a pharmaceutical technology. More specifically, the present invention relates to a pharmaceutical composition comprising glimepiride and a surface active agent. Surface active agent obtainable by reacting castor oil or hydrogenated castor oil with ethylene oxide, preferably hydrogenated castor oil, substantially improves dissolution glimepiride active pharmaceutical ingredient and at the same time, when both formulated into a pharmaceutical compositi...

FIELD: medicine pharmaceutics. ^ SUBSTANCE: invention refers to medicine and more specifically to an antidiabetic composition. What is offered is a pharmaceutical composition containing Glimepiride poloxamer sodium croscarmellose and other excipients - povidone lactose monohydrate microcrystalline cellulose stearic acid salt and a colourant. ^ EFFECT: pharmaceutical composition is characterised by high therapeutic activity satisfactory technical characteristics and shelf life of more than 2 year...

A solid preparation useful as a diabetes-treating agent or the like and excellent in the dissolution properties of an insulin sensitizer and an insulin secretagogue which comprises an insulin sensitizer an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester is provided. In an embodiment there is provided a solid preparation comprising a layer containing pioglitazone or a salt thereof; and a layer containing glimepiride and a polyoxyethylene sorbitan fatty acid ester.

The present invention relates to a pharmaceutical composition for treating or preventing type II diabetes mellitus comprising piperazine dithioctate and glimepiride which is a new combination drug. The pharmaceutical composition of the present invention has strong synergistic effects for treating type II diabetes mellitus by improving metabolic disorders and insulin resistance of diabetic patients as well as lowering blood glucose levels and by increasing glucose uptake in cells compared with si...